业务发展

业务发展

Business development
全部分类

Business Cooperation Modes

As a global CNS-focused pharmaceutical enterprise, we plan to gradually build an industrial ecosystem spanning innovative drug R&D, clinical development, manufacturing and marketing. Leveraging our global strategic partner network and professional cross-border drug registration platform, we provide global pharmaceutical companies with full lifecycle business solutions through an innovative cooperation mechanism of "co-development + mutual empowerment", bridging technical and market value.

I. Co-development - A new paradigm of strategic collaboration

Focusing on CNS innovation, we offer co-development solutions for breakthrough therapies, including innovative drugs and modified new drugs: Utilizing a flexible investment ratio model, both parties share technical resources and development experience in drug screening, clinical research and regulatory submission. During cooperation, a joint decision-making mechanism, alongside an internationally recognized equity distribution system, ensures optimal allocation of intellectual property rights and market access rights.

II. Co-investment - Full-cycle value-added investment

For high-potential projects from IND submission to commercialization, we offer various capital cooperation solutions based on the mutual benefit principle. We design differentiated investment models tailored to project maturity (early R&D/clinical development/marketing preparation), involving multiple financial instruments for equity investment, milestone-based gambling, and dividend preference. Through resource grafting and risk-sharing, we help partners achieve dual goals: enhancing R&D efficiency and multiplying capital value.

III. Product license-in - end-to-end solutions for commercialization in China

With a professional marketing network covering 31 provincial administrative regions (including 50+ strategic cooperation terminals), we offer exclusive sales agency services for overseas pharmaceutical companies. Priority is given to differentiated competitive products, such as modified preparations (e.g., 505b2), high-barrier and special dosage form generic drugs, as well as innovator drugs. We build a professional team to provide all-around support for the marketing of imported drugs in China.

IV.  Product export - dual-channel global expansion strategy

We establish a dual-channel system for cross-border drug circulation: leveraging our MAH-backed products while integrating licensed-in products from overseas strategic partners to create synergistic advantages. Supported by three regional hubs in Europe/USA, Southeast Asia, and the Middle East, we provide one-stop services for local pharmaceutical companies, including regulatory submissions, channel partnerships and localized marketing, aiming to build a strategic hub for global supply of Chinese-made products.